Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)
China · Delayed Price · Currency is CNY 26.86
+0.30 (1.13%)
Sep 30, 2026, 3:00 PM CST
SHA:600976 Revenue
Jianmin Pharmaceutical Group had revenue of 738.07M CNY in the quarter ending June 30, 2026, a decrease of -19.12%. This brings the company's revenue in the last twelve months to 3.18B, down -3.74% year-over-year. In the year 2025, Jianmin Pharmaceutical Group had annual revenue of 3.37B, down -3.85%.
Revenue (ttm)
3.18B
Revenue Growth
-3.74%
P/S Ratio
1.30
Revenue / Employee
1.41M
Employees
2,257
Market Cap
4.12B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.37B | -135.08M | -3.85% |
| Dec 31, 2024 | 3.50B | -708.17M | -16.81% |
| Dec 31, 2023 | 4.21B | 572.35M | 15.72% |
| Dec 31, 2022 | 3.64B | 341.37M | 10.35% |
| Dec 31, 2021 | 3.30B | 843.43M | 34.34% |
| Jan 1, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.18B |
| Jiangsu Lianhuan Pharmaceutical | 3.00B |
| Jinhe Biotechnology CO., LTD. | 2.94B |
| Tibet Weixinkang Medicine | 1.13B |
| LanZhou Foci Pharmaceutical | 926.49M |
| ChengDu ShengNuo Biotec | 911.15M |
| Harbin Medisan Pharmaceutical | 805.09M |
| Shandong Wohua Pharmaceutical | 784.94M |